Aspire Compounding Pharmacy
FDA 503B outsourcing facility
Sugar Land, Texas
Key Takeaways
- FDA-registered 503B outsourcing facility since 2025
- Sterile compounding from bulk substances: Yes
- Not yet inspected by the FDA
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- March 21, 2025
- Most recent registration
- February 24, 2026
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- Not yet inspected
Aspire Compounding Pharmacy has registered with the FDA as a 503B outsourcing facility but has not yet been inspected. The FDA inspects registered facilities on a risk-based schedule once drug production and distribution are confirmed.
Compounded peptides and GLP-1s
Aspire Compounding Pharmacy has not assigned NDCs or filed product reports in the most recent FDA reporting periods. 503B outsourcing facilities are a primary supply route for compounded peptides and GLP-1s during FDA-listed shortages; PeptideGrids grades the evidence for each, including Semaglutide, Tirzepatide, BPC-157, Retatrutide. Browse the GLP-1 and therapeutic peptide databases.
Location
1730 Williams Trace Blvd, Sugar Land, TX 77478
Satellite and street imagery via Esri. Open larger map.
Contact
FDA-registered contact: Akwasi Amankwaah, 1-281-501-0511. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Aspire Compounding Pharmacy with the Texas State Board of Pharmacy.
503B facilities in Texas
Texas has 16 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in Texas.
Frequently asked questions
Is Aspire Compounding Pharmacy registered with the FDA?
Yes. Aspire Compounding Pharmacy is a registered 503B outsourcing facility, first registered with the FDA on March 21, 2025 and most recently registered on February 24, 2026.
Has Aspire Compounding Pharmacy been inspected by the FDA?
Aspire Compounding Pharmacy has registered with the FDA but has not yet been inspected as a 503B outsourcing facility.
Has Aspire Compounding Pharmacy had any FDA drug recalls?
No FDA drug recalls are matched to Aspire Compounding Pharmacy in the openFDA enforcement database.
What does Aspire Compounding Pharmacy compound?
Aspire Compounding Pharmacy has not filed product reports with NDC-assigned drugs in the most recent FDA reporting periods.
Where is Aspire Compounding Pharmacy located?
Aspire Compounding Pharmacy is located in Sugar Land, Texas (1730 Williams Trace Blvd).
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Aspire Compounding Pharmacy. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.